

Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

Recombinant Anti-CLEC9A antibody [EPR22324]

RRID:AB_2884022

Type: Antibody

Proper Citation

Abcam Cat# ab223188, RRID:AB_2884022

Antibody Information

URL: http://antibodyregistry.org/AB_2884022

Proper Citation: Abcam Cat# ab223188, RRID:AB_2884022

Target Antigen: CLEC9A

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: IHC-P, Flow Cyt

Antibody Name: Recombinant Anti-CLEC9A antibody [EPR22324]

Description: This recombinant monoclonal targets CLEC9A

Target Organism: human

Clone ID: EPR22324

Antibody ID: AB_2884022

Vendor: Abcam

Catalog Number: ab223188

Record Creation Time: 20231110T031745+0000

Record Last Update: 20260830T011720+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-CLEC9A antibody [EPR22324].

No alerts have been found for Recombinant Anti-CLEC9A antibody [EPR22324].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Pham FK, et al. (2026) Melanoma cell states shape spatial tumor-immune ecosystems to dictate the efficacy of anti-PD1 immunotherapy. Journal for immunotherapy of cancer, 14(6).

Anadon CM, et al. (2022) Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T??cells. Cancer cell, 40(5), 545.

Papadas A, et al. (2022) Stromal remodeling regulates dendritic cell abundance and activity in the tumor microenvironment. Cell reports, 40(7), 111201.

Chevrier S, et al. (2021) A distinct innate immune signature marks progression from mild to severe COVID-19. Cell reports. Medicine, 2(1), 100166.